Clearmind Medicine Inc.

NasdaqCM CMND

Clearmind Medicine Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending October 31, 2024

Clearmind Medicine Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending October 31, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Clearmind Medicine Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending October 31, 2023 was USD 0.00, a 100.00% change year over year.
Clearmind Medicine Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending October 31, 2022 was USD -5.57 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: CMND

Clearmind Medicine Inc.

CEO	Dr. Adi Zuloff-Shani Ph.D.
IPO Date	Nov. 15, 2022
Location	Canada
Headquarters	1220 West 6th Avenue
Employees	4
Sector	Healthcare
Industries Mental Health Alcoholic Beverages Cosmetics Drugstores & Retail Pharmacies Non-Alcoholic Beverages Pharmaceuticals Soft Drinks & Sodas

Description

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key trends

Past 5 years